A six-year study in a real-world population reveals an increased incidence of dyslipidemia during COVID-19.

Valentina Trimarco,Raffaele Izzo,Stanislovas S Jankauskas,Mario Fordellone,Giuseppe Signoriello,Maria Virginia Manzi,Maria Lembo,Paola Gallo,Giovanni Esposito,Roberto Piccinocchi,Francesco Rozza,Carmine Morisco,Pasquale Mone,Gaetano Piccinocchi,Fahimeh Varzideh,Bruno Trimarco,Gaetano Santulli
{"title":"A six-year study in a real-world population reveals an increased incidence of dyslipidemia during COVID-19.","authors":"Valentina Trimarco,Raffaele Izzo,Stanislovas S Jankauskas,Mario Fordellone,Giuseppe Signoriello,Maria Virginia Manzi,Maria Lembo,Paola Gallo,Giovanni Esposito,Roberto Piccinocchi,Francesco Rozza,Carmine Morisco,Pasquale Mone,Gaetano Piccinocchi,Fahimeh Varzideh,Bruno Trimarco,Gaetano Santulli","doi":"10.1172/jci183777","DOIUrl":null,"url":null,"abstract":"BACKGROUND\r\nRecent studies conducted in COVID-19 survivors suggest that SARS-CoV-2 infection is associated with an increased risk of dyslipidemia. However, it remains unclear whether this augmented risk is confirmed in the general population and how this phenomenon is impacting the overall burden of cardiometabolic diseases.\r\n\r\nMETHODS\r\nTo address these aspects, we conducted a 6-year longitudinal study to examine the broader effects of COVID-19 on dyslipidemia incidence within a real-world population (228,266 subjects) residing in Naples, Southern Italy. The pre-COVID-19 and the COVID-19 groups were balanced for demographic and clinical factors using propensity score matching.\r\n\r\nRESULTS\r\nOur analysis spans over a period of three years during the pandemic (2020-2022), comparing dyslipidemia incidence with pre-pandemic data (2017-2019), with a follow-up time of at least 1,095 days corresponding to 21,349,215 person-years. During the COVID-19 period we detected an increased risk of developing any dyslipidemia when compared with the pre-COVID-19 triennium (OR = 1.29, 95% CI 1.19-1.39). Importantly, these estimates were adjusted for comorbidities by a multivariate analysis.\r\n\r\nCONCLUSIONS\r\nTaken together, our data reveal a notable rise in dyslipidemia incidence amid the COVID-19 pandemic, suggesting to establish specialized clinical monitoring protocols for COVID-19 survivors to mitigate the risk of dyslipidemia development.","PeriodicalId":520097,"journal":{"name":"The Journal of Clinical Investigation","volume":null,"pages":null},"PeriodicalIF":0.0000,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of Clinical Investigation","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1172/jci183777","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
引用次数: 0

Abstract

BACKGROUND Recent studies conducted in COVID-19 survivors suggest that SARS-CoV-2 infection is associated with an increased risk of dyslipidemia. However, it remains unclear whether this augmented risk is confirmed in the general population and how this phenomenon is impacting the overall burden of cardiometabolic diseases. METHODS To address these aspects, we conducted a 6-year longitudinal study to examine the broader effects of COVID-19 on dyslipidemia incidence within a real-world population (228,266 subjects) residing in Naples, Southern Italy. The pre-COVID-19 and the COVID-19 groups were balanced for demographic and clinical factors using propensity score matching. RESULTS Our analysis spans over a period of three years during the pandemic (2020-2022), comparing dyslipidemia incidence with pre-pandemic data (2017-2019), with a follow-up time of at least 1,095 days corresponding to 21,349,215 person-years. During the COVID-19 period we detected an increased risk of developing any dyslipidemia when compared with the pre-COVID-19 triennium (OR = 1.29, 95% CI 1.19-1.39). Importantly, these estimates were adjusted for comorbidities by a multivariate analysis. CONCLUSIONS Taken together, our data reveal a notable rise in dyslipidemia incidence amid the COVID-19 pandemic, suggesting to establish specialized clinical monitoring protocols for COVID-19 survivors to mitigate the risk of dyslipidemia development.
一项为期六年的实际人群研究显示,在 COVID-19 期间,血脂异常的发生率有所增加。
背景最近对 COVID-19 幸存者进行的研究表明,SARS-CoV-2 感染与血脂异常风险增加有关。方法为了解决这些问题,我们进行了一项为期 6 年的纵向研究,以考察 COVID-19 对居住在意大利南部那不勒斯的真实人群(228266 名受试者)中血脂异常发生率的广泛影响。结果我们的分析跨越了大流行期间(2020-2022 年)的三年时间,将血脂异常发生率与大流行前的数据(2017-2019 年)进行了比较,随访时间至少为 1,095 天,相当于 21,349,215 人年。在 COVID-19 期间,与 COVID-19 前的三年期相比,我们发现患任何血脂异常的风险都有所增加(OR = 1.29,95% CI 1.19-1.39)。结论综上所述,我们的数据显示,在 COVID-19 大流行期间,血脂异常的发病率显著上升,建议为 COVID-19 的幸存者制定专门的临床监测方案,以降低血脂异常的发病风险。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
自引率
0.00%
发文量
0
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信